Get All Access for FREEMarket News & Research,
Live Transcripts & Audio,
and a whole lot more…
For full-year 2018, $WHR expects GAAP diluted EPS of $12.45-13.45 and ongoing diluted EPS of $14.50-15.50. The company expects to generate cash from operating activities of approx. $1.7-1.8Bil and free cash flow of approx. $1-1.1Bil for FY18.
$WHR reported a net loss of $268MM or $3.69 per share in 4Q17 compared to a net income of $180MM or $2.36 per share in 4Q16. This includes a one-time non-cash charge of approx. $420MM related to tax reform. 4Q17 ongoing diluted EPS was $4.10. Net sales were $5.7Bil, up 1% compared to the prior-year period.
$LFUS and $IXYS announced the election deadline by which $IXYS stockholders of record may elect to receive cash, shares of $LFUS common stock or both as merger consideration in connection with the $LFUS acquisition of $IXYS. The election deadline is Jan. 12, 2018. The parties expect to close the transaction on Jan. 17, 2018.
$CLX announced the official opening of a new manufacturing facility for the company's Home Care products. Named Atlanta West, the 258,000-sq.ft. facility is adjacent to the company's existing manufacturing facility, called Atlanta Main. The opening of Atlanta West has created about 100 jobs in Clayton County.
$ASH is combining its nutrition business with the ingredients processing expertise of the recently-acquired Pharmachem with the goal of expanding into the fast-growing global nutraceuticals market. The combined unit, which will be called Health and Wellness, will continue to report up through $ASH’s Specialty Ingredients segment.
$ASH plans to nominate Jerome Peribere as a new independent director for election at its upcoming 2018 Annual Meeting. If elected, it is also intended that Peribere will serve as a member of the compensation committee. George Schaefer Jr. will not be nominated for re-election to the board.
$IPHS has acquired NutraGenesis, a Vermont-based marketer of branded nutraceutical ingredients, for a total purchase price of $28MM in cash. $IPHS funded the acquisition with borrowings under its existing credit facility. The acquisition is expected to be accretive to the company’s EPS in the first year following the close of the transaction.
For full-year 2017, $WHR expects GAAP EPS of $11.10-11.40 and ongoing EPS of $13.60-13.90. The company expects to generate cash from operating activities of $1.55-1.6Bil and free cash flow of approx. $900MM. Capital spending is expected to be $650-700MM for 2017.
$WHR reported net income of $276MM or $3.72 per share in 3Q17 compared to $238MM or $3.10 per share in 3Q16. GAAP net earnings were positively impacted by lower income tax expense of approx. $65MM during 3Q17. Ongoing EPS was $3.83 in 3Q17. Net sales were $5.4Bil, an increase of more than 3% versus last year.
$WST, a pharmaceutical services firm, said a recent study showed its injection guide ID Adaptor could be used for administering intradermal injections in a safe and effective manner. The clinical trial evaluated the feasibility of conducting a door-to-door vaccination campaign to administer Fractional Inactivated Poliovirus Vaccine to children.